Pancreatic Cancer Clinical Trials in Arizona

Showing 101-120 of 120 trials

Pancreatic Cancer Serum and DNA Repository

NCT00296114

To prospectively collect serum and DNA samples from subjects with pancreatic cancer, pancreatitis, liver disease, and from healthy and at-risk volunteers in order to identify novel biomarkers for early diagnosis, differential diagnosis, stage, natural history of the disease, response to treatment, and to identify novel targets for therapeutic interventions. In particular:

Pancreas Cancer

Pancreatic Cancer Research Team690 participantsStarted Feb 2004

Scottsdale, Arizona, United States • Tucson, Arizona, United States • Los Angeles, California, United States +7 more locations

COMPLETEDPhase 331 miles

Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT00058149

RATIONALE: Drugs used in chemotherapy such as gemcitabine and oxaliplatin use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. It is not yet known whether gemcitabine is more effective with or without oxaliplatin in treating pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without oxaliplatin in treating patients who have locally advanced or metastatic pancreatic cancer.

Pancreatic Cancer

Eastern Cooperative Oncology GroupStarted Mar 2003

Huntsville, Alabama, United States • Scottsdale, Arizona, United States • Aurora, Colorado, United States +58 more locations

Pancreatic Cancer Serum and DNA Repository

Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer Trials in Other Cities

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

BMS-247550 in Treating Patients With Advanced Pancreatic Cancer

A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer

APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

Other Conditions in Arizona